Joseph Galanko

University of North Carolina at Chapel Hill

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Robert S. Sandler

University of North Carolina at Chapel Hill

Temitope O. Keku

University of North Carolina at Chapel Hill

Nicholas J. Shaheen

University of North Carolina at Chapel Hill

Anne F. Peery

University of North Carolina at Chapel Hill

Evan S. Dellon

University of North Carolina at Chapel Hill

Michael D. Kappelman

University of North Carolina at Chapel Hill

Edward L. Barnes

University of North Carolina at Chapel Hill

Christopher F. Martin

University of North Carolina at Chapel Hill

Christopher Martin

University of Leicester

Michael Fried

Target (United States)

Cooperative Institutions

University of North Carolina at Chapel Hill

University of North Carolina Health Care

Harvard University

Indiana University School of Medicine

Cincinnati Children's Hospital Medical Center

University of Michigan–Ann Arbor

Massachusetts General Hospital

Northwestern University

Texas A&M University

Boston Children's Hospital

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Pantoprazole reduces the size of postbanding ulcers after variceal band ligation: A randomized, controlled trial

Hepatology (2005)

Nicholas J. Shaheen Eugene Stuart Sarah Schmitz Kate L. Mitchell Michael Fried

Elective esophageal variceal ligation (EVL) is performed to decrease the risk of variceal hemorrhage. Side effects of EVL include hemorrhage, chest pain, dysphagia, and odynophagia. Because gastric acid may exacerbate postbanding ulcers and delay healing, proton pump inhibition may decrease side effects associated with EVL. The aim of this study was to assess the efficacy of pantoprazole, a proton pump inhibitor, as an adjunct to elective EVL. We performed a double-blinded, randomized, placebo-controlled trial of pantoprazole after elective EVL. Subjects in the pantoprazole arm received 40 mg pantoprazole intravenously after EVL followed by 40 mg oral pantoprazole for 9 days. Control subjects received intravenous and oral placebo. Subjects underwent upper endoscopy 10 to 14 days after banding. Primary outcomes included the size and number of ulcers and the subjects' reports of dysphagia, chest pain, and heartburn. Forty-four subjects were randomized: 42 completed the protocol. At follow-up endoscopy, the mean number of ulcers was similar in the two groups. However, the ulcers in the pantoprazole group were on average half as large as in the placebo group (37 mm(2) vs. 82 mm(2), P < .01). Chest pain, dysphagia, and heartburn scores were not significantly different. Four subjects, all in the placebo group, had adverse outcomes, including 3 who bled from postbanding ulcers and 1 with sepsis. In conclusion, subjects receiving pantoprazole after elective EVL had significantly smaller postbanding ulcers on follow-up endoscopy than subjects receiving placebo. However, the total ulcer number and patient symptoms were not different between the groups.

Pantoprazole

10.1002/hep.20593

Cite

Citations (191)

Sa2007 – Aspirin/Nsaid Use Greater Than 4 Years Reduces Inflammatory-Associated Microsatellite Alterations in Proximal Colorectal Cancer (CRC) and Improves Patient Overall Survival

Gastroenterology (2019)

Yoshiki Okita Minoru Koi Erika Koeppe Elena M. Stoffel Joseph Galanko

Microsatellite Instability

10.1016/s0016-5085(19)38030-8

Cite

Citations (0)

Alterations in Intestinal Transit in Subgroups of Patients with Functional Bowel Disorders and Healthy Controls - A Wireless Motility Capsule Study

The American Journal of Gastroenterology (2010)

Yehuda Ringel Daniel Gelfond Joseph Galanko Danielle Maier Tamara OʼHara

Purpose: Wireless motility capsule (WMC) was recently introduced as a validated tool to measure gastric emptying (GE) and colonic transit time (CTT). However, there is no data on the reproducibility of these measures over time. Aim: To investigate the reproducibility of measurement of intestinal segmental transit time (TT) and whole gut transit time (WGTT) by SmartPill WMC. Methods: We studied a total of 27 subjects including non-patients subjects with mild functional bowel symptoms (group I, n=17) and healthy subjects with no GI symptoms (Group II, n=10). WMC was used to measure GET and CTT (primary variables) as well as WGTT and small bowel transit time (SBTT) (secondary variables). A-priori hypothesis was that ≥80% subjects will not change their diagnostic category (from ‘Normal’ to ‘Abnormal’ or vice versa) for the two primary variables on a test-retest evaluation 4 weeks apart. The variability in intestinal transit over time was also assessed. Comparisons of transit time variables between the groups were done using student t-tests/ANOVA. Results: The percent of subjects that stayed within the same category during test-retest evaluations is provided in Table 1. More than 85% of subjects did not change their diagnostic category for all tested variables on a test-retest evaluation. The percent of subjects that had greater than 35% variability in test-re-test were 33.3% (8/24) for GET, 53.9% (14/26) for CTT, 29.2% (7/24) for SBTT, and 50% (13/26) for WGTT. There were no differences in percent variability between the groups.[1347] Table 1. Percent of subjects who did not change diagnostic category on test-retest evaluationConclusion: We provide evidence for high reproducibility of WMC measurements of all study variables. Considerable number of subjects has greater than 35% change in test-retest transit time. This finding is consistent with normal day to day intestinal transit variability observed with other transit measures. Disclosure: Dr Ringel and Ms. Maier recieved Grant/Reseasrch support from SmartPill. Jack Semler is SmartPill employee. Drs. Borowitz and Gelfond recieved Grant/Reseasrch support from SmartPill.

Transit time

Gastrointestinal transit

10.14309/00000434-201010001-01347

Cite

Citations (2)

Local IGFBP-3 mRNA expression, apoptosis and risk of colorectal adenomas

BMC Cancer (2008)

Temitope O. Keku Robert S. Sandler James G. Simmons Joseph Galanko John T. Woosley

IGF binding protein-3 (IGFBP-3) regulates the bioavailability of insulin-like growth factors I and II, and has both anti-proliferative and pro-apoptotic properties. Elevated plasma IGFBP-3 has been associated with reduced risk of colorectal cancer (CRC), but the role of tissue IGFBP-3 is not well defined. We evaluated the association between tissue or plasma IGFBP-3 and risk of colorectal adenomas or low apoptosis. Subjects were consenting patients who underwent a clinically indicated colonoscopy at UNC Hospitals and provided information on diet and lifestyle. IGFBP-3 mRNA in normal colon was assessed by real time RT-PCR. Plasma IGFBP-3 was measured by ELISA and apoptosis was determined by morphology on H & E slides. Logistic regression was used to compute odds ratio (OR) and 95% confidence intervals. We observed a modest correlation between plasma IGFBP-3 and tissue IGFBP-3 expression (p = 0.007). There was no significant association between plasma IGFBP-3 and adenomas or apoptosis. Tissue IGFBP-3 mRNA expression was significantly lower in cases than controls. Subjects in the lowest three quartiles of tissue IGFBP-3 gene expression were more likely to have adenomas. Consistent with previous reports, low apoptosis was significantly associated with increased risk of adenomas (p = 0.003). Surprisingly, local IGFBP-3 mRNA expression was inversely associated with apoptosis. Low expression of IGFBP-3 mRNA in normal colonic mucosa predicts increased risk of adenomas. Our findings suggest that local IGFBP-3 in the colon may directly increase adenoma risk but IGFBP-3 may act through a pathway other than apoptosis to influence adenoma risk.

Colorectal adenoma

Surgical oncology

10.1186/1471-2407-8-143

Cite

Citations (22)

Variations in Therapy for Inflammatory Bowel Disease among African American Patients Compared to other Racial Groups

Gastroenterology (2017)

Edward L. Barnes Bharati Kochar Joel Pekow Ashwin N. Ananthakrishnan Christopher Martin

Racial group

10.1016/s0016-5085(17)31454-3

Cite

Citations (0)